Long-Acting Peptide Analogs via Polymeric Carriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for peptides and proteins face challenges such as short biological half-lives due to renal clearance and proteolysis, requiring frequent administrations and being impractical for outpatient use, especially in conditions like cirrhosis and hepatorenal syndrome where long-acting vasoconstrictors are needed.
Innovation Solution
Development of long-acting vasopressin analogs with modified binding moieties and polymeric carriers for slow release, allowing for sustained activation and prolonged half-life, enabling once-daily or less frequent administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional peptide formulations are used, then the peptides can be administered easily, but they have short biological half-lives requiring frequent administrations
Solution Approach 1:
The patent employs polymeric carriers as intermediary substances that bind to peptide analogs and facilitate their sustained release in vivo. These polymeric carriers act as mediators between the administered peptide and the biological system, controlling the release rate to extend half-life while maintaining ease of administration through reduced frequency.
Solution Approach 2:
The patent modifies the physical and chemical parameters of peptides by creating analogs with altered structures (e.g., fatty acid modifications, amino acid substitutions) that resist proteolysis and renal clearance. These parameter changes in molecular structure directly extend biological half-life while the polymeric carrier system further modulates release kinetics.
2Duration of action of moving object
If peptides are modified to resist proteolysis and renal clearance, then half-life is extended, but the complexity of peptide structure increases
Solution Approach 1:
The patent segments the peptide structure by separating the active peptide component from the modifying components (fatty acid chains, amino acid substitutions). This segmentation allows the core peptide to maintain its biological activity while the attached moieties provide protection against degradation, managing complexity through functional separation.
Solution Approach 2:
The patent creates composite peptide structures by combining the active peptide sequence with protective moieties such as fatty acid chains and modified amino acids. These composite structures integrate multiple functions (activity, stability, resistance to clearance) into a single molecular entity, extending half-life while controlling complexity through deliberate compositional design.
3Duration of action of moving object
If polymeric carriers are used for slow release, then sustained activity is achieved, but the formulation complexity increases
Solution Approach 1:
The polymeric carriers serve as intermediary delivery systems that simplify the formulation complexity by providing a pre-designed, off-the-shelf platform for sustained release. Rather than designing complex release mechanisms from scratch, the patent utilizes these intermediary polymeric systems that already possess controlled release properties, thereby achieving sustained activity with manageable formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified vasopressin analogs provide sustained vasopressin activity, improving hemodynamic balance and organ perfusion, and are effective in conditions like cirrhosis, hepatorenal syndrome, and septic shock, reducing the need for frequent injections and improving patient quality of life.
Implementation Method 1
The bond connecting the peptide to the carrier is cleaved in vivo by host proteases or by hydrolysis
Implementation Method 2
The binding moiety is capable of binding to a polymeric carrier
Data Source
AI summary
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidiodacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.